NCT03984838View on ClinicalTrials.gov

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

August 13, 2019

Study Completion Date

August 13, 2019

Conditions
HIV Infections
Interventions
DRUG

JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet

JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.

Trial Locations (1)

91206

GSK Investigational Site, Glendale

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
collaborator

Janssen, LP

INDUSTRY

lead

ViiV Healthcare

INDUSTRY